The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia.
Adult
Age Factors
Aged
Aged, 80 and over
Australia
Dyslipidemias
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ complications
Male
Middle Aged
Protein Kinase Inhibitors
/ therapeutic use
Pyrimidines
/ adverse effects
Retrospective Studies
Safety-Based Drug Withdrawals
Vascular Diseases
/ chemically induced
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
09 04 2019
09 04 2019
Historique:
received:
05
11
2018
accepted:
19
02
2019
entrez:
5
4
2019
pubmed:
5
4
2019
medline:
24
7
2020
Statut:
ppublish
Résumé
Although second-generation tyrosine kinase inhibitors (TKIs) show superiority in achieving deep molecular responses in chronic myeloid leukemia in chronic phase (CML-CP) compared with imatinib, the differing adverse effect (AE) profiles need consideration when deciding the best drug for individual patients. Long-term data from randomized trials of nilotinib demonstrate an increased risk of vascular AEs (VAEs) compared with other TKIs, although the natural history of these events in response to dose modifications or cessation has not been fully characterized. We retrospectively reviewed the incidence of nilotinib-associated AEs in 220 patients with CML-CP at 17 Australian institutions. Overall, AEs of any grade were reported in 95 patients (43%) and prompted nilotinib cessation in 46 (21%). VAEs occurred in 26 patients (12%), with an incidence of 4.1 events per 100 patient-years. Multivariate analysis identified age (
Identifiants
pubmed: 30944100
pii: bloodadvances.2018028035
doi: 10.1182/bloodadvances.2018028035
pmc: PMC6457217
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Pyrimidines
0
nilotinib
F41401512X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1084-1091Informations de copyright
© 2019 by The American Society of Hematology.
Références
Blood Adv. 2017 May 15;1(13):802-811
pubmed: 29296724
Ann Hematol. 2015 Mar;94(3):393-7
pubmed: 25304102
Leuk Lymphoma. 2016;57(6):1300-10
pubmed: 26373533
Intern Med J. 2018 Feb;48 Suppl 2:5-13
pubmed: 29388307
Blood. 2015 Feb 5;125(6):915-23
pubmed: 25519749
Int J Hematol. 2013 Jan;97(1):135-8
pubmed: 23179903
Leuk Res. 2017 Aug;59:47-54
pubmed: 28549238
Blood. 2013 Aug 8;122(6):872-84
pubmed: 23803709
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):110-114
pubmed: 29222244
Thromb Res. 2016 Sep;145:54-64
pubmed: 27494773
Leukemia. 2016 May;30(5):1044-54
pubmed: 26837842
Leukemia. 2017 Nov;31(11):2529-2531
pubmed: 28862704
Ann Intern Med. 2016 Aug 2;165(3):161-6
pubmed: 27295519
Leukemia. 2013 Jun;27(6):1316-21
pubmed: 23459449
Am J Hematol. 2011 Jul;86(7):533-9
pubmed: 21538470
Haematologica. 2014 Jul;99(7):1197-203
pubmed: 24658819
J Natl Cancer Inst. 2011 Sep 7;103(17):1347-8
pubmed: 21813414
Leukemia. 2017 Nov;31(11):2388-2397
pubmed: 28757617
Leukemia. 2016 Aug;30(8):1648-71
pubmed: 27121688
N Engl J Med. 2010 Jun 17;362(24):2251-9
pubmed: 20525993
Br J Haematol. 2017 Oct;179(2):219-228
pubmed: 28699641